CONTENTS:
- Research is needed to understand substance use disorders in old adulthood [Editorial]. Behrendt S., p. 600-602.
- Addiction's policy on fair authorship and acknowledgment practices [Editorial]. Cox S., O'Reilly J., West R., Neale J., p. 603-604.
- HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. Rahimi J., Gholami J., Amin-Esmaeili M., Fotouhi A., Rafiemanesh H., Shadloo B., et al., p. 605-622.
- What do HIV-positive drug users' experiences tell us about their antiretroviral medication-taking? An international integrated literature review. Ho I.S., Holloway A., Stenhouse R., p. 623-652.
- Commentary on Ho et al. (2020): Managing people with HIV and drug problems is complex and multi-faceted. Farrell M., Robertson R., p. 653-654.
- Alcohol control policy and changes in alcohol-related traffic harm. Rehm J., Manthey J., Lange S., Badaras R., Zurlyte I., Passmore J., et al., p. 655-665.
- Commentary on Rehm et al. (2020): Alcohol control policy and changes in alcohol-related traffic harm. Jasilionis D., p. 666-667.
- Documented brief intervention associated with reduced linkage to specialty addictions treatment in a national sample of VA patients with unhealthy alcohol use with and without alcohol use disorders. Frost M.C., Glass J.E., Bradley K.A., Williams E.C., p. 668-678.
- Commentary on Frost et al. (2020): The end of SBIRT and a new continuum of care. Willenbring M., p. 679-680.
- Washington's privatization of liquor: effects on household alcohol purchases from Initiative 1183. Barnett S.B.L., Coe N.B., Harris J.R., Basu A., p. 681-689.
- Valuing families' preferences for drug treatment: a discrete choice experiment. Shanahan M., Seddon J., Ritter A., De Abreu Lourenco R., p. 690-699.
- Commentary on Shanahan et al. (2020): The importance of quantifying the intangible costs for family members of drug users. Mosquera-Nogueira J., p. 700-701.
- Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation. Hancock E., Ward Z., Ayres R., Neale J., Hussey D., Kesten J.M., et al., p. 702-713.
- Commentary on Hancock et al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs. Platt L., Harris M., Sweeney S., p. 714-715.
- New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer drug samples and poisons center exposures between 2013 and 2017. Hondebrink L., Nugteren-van Lonkhuyzen J.J., Hunault C.C., van den Berg J., van der Gouwe D., van Riel A., p. 716-725.
- The role of personality functioning in drug misuse treatment engagement. Papamalis F.E., Kalyva E., Teare M.D., Meier P.S., p. 726-739.
- Transitions across tobacco use profiles among adolescents: results from the Population Assessment of Tobacco and Health (PATH) study waves 1 and 2. Simon P., Buta E., Gueorguieva R., Kong G., Morean M.E., Camenga D.R., et al., p. 740-747.
- Changes in smoker characteristics in England between 2008 and 2017. Garnett C., Tombor I., Beard E., Jackson S.E., West R., Brown J., p. 748-756.
- Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users. St Helen G., Nardone N., Addo N., Dempsey D., Havel C., Jacob P., 3rd, et al., p. 757-767.
- Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study. Brenner P., Brandt L., Li G., DiBernardo A., Boden R., Reutfors J., p. 768-777.
- Fentanyl is used in Mexico's northern border: current challenges for drug health policies. Fleiz C., Arredondo J., Chavez A., Pacheco L., Segovia L.A., Villatoro J.A., et al., p. 778-781.
- Vitamin E acetate is not present in licit e-cigarette products available on the UK market. Nyakutsikwa B., Britton J., Bogdanovica I., Langley T., p. 782-783.
- Safer injecting facilities-is the research there? A comment on Caulkins et al. (2019). Belackova V., Salmon A.M., Jauncey M., Day C.A., p. 784-785.
- Disagreeing on whether we agree. Caulkins J.P., Kilmer B., Pardo B., p. 785-786.
- Commentary on Rhee & Rosenheck (2019): Buprenorphine prescribing for opioid use disorder in medical practice - can office-based out-patient care address the opiate crisis in the United States? Frank J.W., Binswanger I.A., p. 786-787.